IN THE CLAIMS:

Please amend claims 1, 5, 10, 15, 21, 23, and 26-30.

No new matter has been added.

This listing of claims will replace all prior versions, and listings, of claims in the application:

1 . (Currently amended) A transgenic mouse comprising a modified glycoprotein V (GP V) gene, wherein at least one allele of said gene has been modified ~~so that the mouse does not express a functional GP V protein or expresses a GPV protein which demonstrates a reduced functionality as compared with the native or wild-type GP V protein~~ by a construct which removes a sequence of GP V comprising nucleotides encoding Met 1 to Leu 389 of SEQ ID NO:12 and wherein said mouse has a decreased bleeding time compared to a mouse homozygous for the wild type GP V gene.

2. (canceled)

3. (Previously presented) Platelets isolated from blood plasma of the mouse of claim 1.

4. (canceled)

5. (Currently amended) A method of preparing a transgenic mouse comprising a modified glycoprotein V gene, wherein at least one allele of said gene has been modified ~~so that the mouse does not express a functional GP V protein or expresses a GPV protein which demonstrates a reduced functionality as compared with the native or wild-type GP V protein~~ by a construct which removes a sequence of GP V comprising nucleotides encoding Met 1 to Leu 389 of SEQ ID NO:12 ~~and wherein said mouse has a decreased bleeding time~~, said method comprising:

a) introducing into embryonic stem cells a nucleic acid molecule encoding a modified GP V gene; ~~and~~

b) generating a transgenic mouse from the cells resulting from step a); and

c) determining that the bleeding time of the transgenic mouse is less than the bleeding time of a mouse homozygous for the GP V gene.

6. (canceled)

7. (canceled)

8. (Previously presented) The method of claim 5 further comprising the step of breeding the transgenic mouse so as to produce a mouse homozygotic for the modified GP V gene.

9. (canceled)

10. (Currently amended) A method of preparing a transgenic mouse comprising a nonfunctional glycoprotein V gene, wherein at least one allele of said gene has been modified ~~so that the mouse does not express a functional GP V protein or expresses a GPV protein which demonstrates a reduced functionality as compared with the native or wild-type GP V protein~~ by a construct which removes a sequence of GP V comprising nucleotides encoding Met 1 to Leu 389 of SEQ ID NO:12 ~~and wherein said mouse has a decreased bleeding time~~, said method comprising:

a) introducing into embryonic stem cells a nucleic acid molecule encoding a disrupted or nonfunctional GP V gene and a selectable marker;
b) identifying and selecting transformed cells;
c) injecting the transformed cells from step b) into blastocysts; and,
d) generating a transgenic mouse from the blastocysts of step c), wherein the generated transgenic mouse is chimeric for the disrupted or nonfunctional GP V gene and wherein said mouse has a decreased bleeding time compared to a mouse homozygous for the wild type GP V gene.

11. (canceled)

12. (canceled)

13. (Previously presented) The method of claim 10 further comprising the following steps:

e) breeding the chimeric mouse with a wild-type mouse to produce a mouse heterozygotic for the nonfunctional GP V gene;
f) crossing a heterozygotic mouse produced in step e) with a chimeric mouse or a heterozygotic mouse; and,
g) selecting a mouse homozygotic for the nonfunctional GP V gene from the resulting progeny.

14. (canceled)

15. (Currently amended) A method to identify an agent that modulates a thrombotic response of a transgenic mouse having a modified GP V gene, wherein at least one allele of said gene has been modified ~~so that the mouse does not express a functional GP V protein or expresses a GPV protein which demonstrates a reduced functionality as compared with the native or wild-type GP V protein~~ by a construct which removes a sequence of GP V comprising nucleotides encoding Met 1 to Leu 389 of SEQ ID NO:12 and wherein said mouse has a decreased bleeding time compared to a mouse homozygous for the wild type GP V gene, comprising the step of exposing the mouse to the agent and determining whether the agent modulates the thrombotic response.

16 - 20 (canceled)

21. (Currently amended) A method of determining the effect of an agent on a characteristic of a mouse that is attributable to the expression of the GP V gene, wherein at least one allele of said gene has been modified ~~so that the mouse does not express a functional GP V protein or expresses a GPV protein which demonstrates a reduced functionality as compared with the native or wild-type GP V protein~~ by a construct which removes a sequence of GP V comprising nucleotides encoding Met 1 to Leu 389 of SEQ ID NO:12 and wherein said mouse has a decreased bleeding time compared to a mouse homozygous for the wild type GP V gene, and wherein said characteristic is platelet function, said method comprising;

a) administering said agent to the mouse of claim 1;

b) maintaining said mouse for a desired period of time after said administration; and,

c) determining whether the characteristic of said mouse that is attributable to the expression of the modified GP V gene has been affected by the administration of said agent.

22. (canceled)

23. (Currently amended) A cell ~~line~~ isolated from a transgenic mouse that comprises a transgene stably integrated into the mouse's genome, said transgene encoding a modified glycoprotein V gene, wherein at least one allele of said gene has been modified ~~so that the mouse does not express a functional GP V protein or expresses a GPV protein which~~

~~demonstrates a reduced functionality as compared with the native or wild-type GP V protein~~ by a construct which removes a sequence of GP V comprising nucleotides encoding Met 1 to Leu 389 of SEQ ID NO:12 and wherein said mouse has a decreased bleeding time compared to a mouse homozygous for the wild type GP V gene.

24. (Currently amended) The cell ~~line~~ of claim 23, wherein said transgene has been introduced into said mouse or an ancestor of said mouse via homologous recombination in embryonic stem cells, and further wherein said mouse expresses a modified GP V protein.

25. (canceled)

26. (Currently amended) The ~~cell~~ line of claim 24, wherein said mouse is fertile and transmits the modified GP V gene to its offspring.

27. (Currently amended) The ~~cell~~ line of claim 23, wherein the modified GP V protein is nonfunctional.

28. (Currently amended) A method of determining the effect of an agent on a characteristic of a mouse that is attributable to the expression of the GP V gene, wherein at least one allele of said gene has been modified ~~so that the mouse does not express a functional GP V protein or expresses a GPV protein which demonstrates a reduced functionality as compared with the native or wild-type GP V protein~~ by a construct which removes a sequence of GP V comprising nucleotides encoding Met 1 to Leu 389 of SEQ ID NO:12 and wherein said mouse has a decreased bleeding time compared to a mouse homozygous for the wild type GP V gene, and wherein said characteristic is hemostasis, said method comprising;

a) administering said agent to the mouse of claim 1;

b) maintaining said mouse for a desired period of time after said administration; and,

c) determining whether the characteristic of said mouse that is attributable to the expression of the modified GP V gene has been affected by the administration of said agent.

29. (Currently amended) A method of determining the effect of an agent on a characteristic of a mouse that is attributable to the expression of the GP V gene, wherein at least one allele of said gene has been modified ~~so that the mouse does not express a functional GP V protein or expresses a GPV protein which demonstrates a reduced functionality as compared with the native or wild-type GP V protein~~ by a construct which removes a sequence of GP V comprising nucleotides encoding Met 1 to Leu 389 of SEQ ID NO:12 and wherein said mouse has a decreased bleeding time compared to a mouse homozygous for the wild type GP V gene, and wherein said characteristic is coagulation, said method comprising;

a) administering said agent to the mouse of claim 1;

b) maintaining said mouse for a desired period of time after said administration; and,

c) determining whether the characteristic of said mouse that is attributable to the expression of the modified GP V gene has been affected by the administration of said agent.

30. (Currently amended) A method of determining the effect of an agent on a characteristic of a mouse that is attributable to the expression of the GP V gene, wherein at least one allele of said gene has been modified ~~so that the mouse does not express a functional GP V protein or expresses a GPV protein which demonstrates a reduced functionality as compared with the native or wild-type GP V protein~~ by a construct which removes a sequence of GP V comprising nucleotides encoding Met 1 to Leu 389 of SEQ ID NO:12 and wherein said mouse has a decreased bleeding time compared to a mouse homozygous for the wild type GP V gene, and wherein said characteristic is thrombosis, said method comprising;

a) administering said agent to the mouse of claim 1;

b) maintaining said mouse for a desired period of time after said administration; and,

c) determining whether the characteristic of said mouse that is attributable to the expression of the modified GP V gene has been affected by the administration of said agent.